Monitor for any future strategic or pipeline announcements that may benefit from Dr. Scott's regulatory expertise, but this appointment alone does not signal a near-term catalyst.
Price Chart
Executive Summary
Arcutis Biotherapeutics appointed Dr. Robert Scott, former AbbVie Chief Medical Officer, to its Board of Directors effective October 23, 2026. Dr. Scott brings extensive pharmaceutical development and regulatory experience. The filing is a routine board appointment with no financial impact.
Key Facts
- Board increased from 10 to 11 directors and appointed Dr. Robert Scott as a Class II director with term expiring at the 2028 annual meeting.
- Dr. Scott is a former Chief Medical Officer and Head of Development at AbbVie (2016-2020) and previously held senior roles at Amgen, Pfizer, and other pharmaceutical companies.
- Dr. Scott received an initial stock option award for 20,507 shares and is eligible for a prorated annual equity award valued at approximately $350,000 and cash retainers of $50,000 for board service and $5,000 for committee service.
- The board determined Dr. Scott qualifies as an independent director under SEC and Nasdaq rules.
- No material transactions or arrangements exist between Dr. Scott and the company beyond standard director compensation.
Financial Impact
Director compensation: initial option for 20,507 shares, prorated annual equity ~$350,000, cash retainer $50,000 plus $5,000 committee fee. Immaterial relative to $4.0B market cap.
Risk Factors
- No financial or operational changes accompany this board appointment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-067752 |
| Exhibit: exhibit991prrobscottmdbo.htm | 0001628280-26-067752 |
| Document: 0001628280-26-067752-index-headers.html | 0001628280-26-067752 |
| Document: 0001628280-26-067752-index.html | 0001628280-26-067752 |
| Document: 0001628280-26-067752.txt | 0001628280-26-067752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 3 | $31.07 | awaiting T+20 | awaiting T+20 | $31.97 (+2.90%) |
Oct 28, 2026 1d ago | 8-K | $31.45 | awaiting T+20 | awaiting T+20 | $31.97 (+1.65%) |
Oct 21, 2026 8d ago | Press Release | $32.20 | awaiting T+20 | awaiting T+20 | $31.97 (−0.71%) |
Oct 5, 2026 24d ago | SC 13G/A | $25.15 | awaiting T+20 | awaiting T+20 | $31.97 (+27.12%) |
Sep 29, 2026 4w ago | Press Release | $26.75 $31.68 | ▲ +18.43% | ▲ +17.72% | $31.97 (+19.51%) |
Sep 18, 2026 5w ago | Insider Cluster | $25.96 $31.89 | ▲ +22.84% | ▲ +23.75% | $31.97 (+23.15%) |
Sep 17, 2026 6w ago | Insider Cluster | $25.38 $28.82 | ▲ +13.55% | ▲ +13.35% | $31.97 (+25.97%) |
Aug 24, 2026 9w ago | Insider Cluster | $24.86 $26.38 | ▲ +6.11% | ▲ +5.87% | $31.97 (+28.60%) |
Aug 21, 2026 9w ago | Insider Cluster | $24.78 $27.78 | ▲ +12.11% | ▲ +10.81% | $31.97 (+29.02%) |
Aug 19, 2026 10w ago | Insider Cluster | $25.35 $25.38 | ▲ +0.12% | ▲ +0.12% | $31.97 (+26.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers